Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1999-04-01

AUTHORS

S Kulkarni, M Rodriguez, A Lafuente, P Mateos, J Mehta, S Singhal, R Saso, D Tait, JG Treleaven, RL Powles

ABSTRACT

Seventeen patients who developed hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation were treated with recombinant tissue plasminogen activator (rtPA) with or without heparin. rtPA was started a median of 13 days post transplant (range 4–35). All patients received rtPA at a dose of 10 mg/day as a starting dose, and 12 patients also received heparin (1500 U bolus; then 100 U/kg/day as a continuous i.v. infusion). The median number of days of rtPA therapy was 2.5 (1–12). The median total serum bilirubin level was 116 mmol/l (range 63–194) at the beginning of treatment. Six patients showed a response to rtPA treatment (29%). It was observed that by day 2 of rtPA therapy, bilirubin levels in responders showed a downwards trend as compared to those in non-responders. In all except one patient this response was observed after two doses of rtPA. Seven out of the 11 non-responders had a past history of liver dysfunction, compared with none of the responders. There were no differences between the two groups in terms of day of onset of liver dysfunction, manifestations of disease, maximum bilirubin and creatinine levels, and day of commencing treatment. No patient experienced severe hemorrhagic complications during therapy. Four responders survived for more than 100 days compared to none of the non-responders. Probability of survival was 33% at day 100. It is difficult to unequivocally establish the role of rtPA in the treatment of VOD. The importance of bilirubin levels on days 2 or 3 of therapy in predicting outcome should be established, as should the optimum dose of rtPA and optimum duration of therapy. More... »

PAGES

803-807

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bmt.1701654

DOI

http://dx.doi.org/10.1038/sj.bmt.1701654

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007632827

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10231143


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bilirubin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatic Veno-Occlusive Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Plasminogen Activator", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kulkarni", 
        "givenName": "S", 
        "id": "sg:person.0776532017.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776532017.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Haematology Department, Hospital La Paz1, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Haematology Department, Hospital La Paz1, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodriguez", 
        "givenName": "M", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Haematology Department, Hospital La Paz1, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Haematology Department, Hospital La Paz1, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lafuente", 
        "givenName": "A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Haematology Department, Hospital La Paz1, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Haematology Department, Hospital La Paz1, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mateos", 
        "givenName": "P", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mehta", 
        "givenName": "J", 
        "id": "sg:person.01145473407.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145473407.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Singhal", 
        "givenName": "S", 
        "id": "sg:person.01224530271.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224530271.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Haematology, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saso", 
        "givenName": "R", 
        "id": "sg:person.0700414221.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700414221.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tait", 
        "givenName": "D", 
        "id": "sg:person.0753037103.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Haematology, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Treleaven", 
        "givenName": "JG", 
        "id": "sg:person.016453351654.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016453351654.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Powles", 
        "givenName": "RL", 
        "id": "sg:person.016072203544.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016072203544.57"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1999-04-01", 
    "datePublishedReg": "1999-04-01", 
    "description": "Seventeen patients who developed hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation were treated with recombinant tissue plasminogen activator (rtPA) with or without heparin. rtPA was started a median of 13 days post transplant (range 4\u201335). All patients received rtPA at a dose of 10 mg/day as a starting dose, and 12 patients also received heparin (1500 U bolus; then 100 U/kg/day as a continuous i.v. infusion). The median number of days of rtPA therapy was 2.5 (1\u201312). The median total serum bilirubin level was 116 mmol/l (range 63\u2013194) at the beginning of treatment. Six patients showed a response to rtPA treatment (29%). It was observed that by day 2 of rtPA therapy, bilirubin levels in responders showed a downwards trend as compared to those in non-responders. In all except one patient this response was observed after two doses of rtPA. Seven out of the 11 non-responders had a past history of liver dysfunction, compared with none of the responders. There were no differences between the two groups in terms of day of onset of liver dysfunction, manifestations of disease, maximum bilirubin and creatinine levels, and day of commencing treatment. No patient experienced severe hemorrhagic complications during therapy. Four responders survived for more than 100 days compared to none of the non-responders. Probability of survival was 33% at day 100. It is difficult to unequivocally establish the role of rtPA in the treatment of VOD. The importance of bilirubin levels on days 2 or 3 of therapy in predicting outcome should be established, as should the optimum dose of rtPA and optimum duration of therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bmt.1701654", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "recombinant tissue plasminogen activator", 
      "veno-occlusive disease", 
      "hepatic veno-occlusive disease", 
      "tissue plasminogen activator", 
      "bilirubin levels", 
      "rtPA therapy", 
      "liver dysfunction", 
      "day 2", 
      "treatment of VOD", 
      "hematopoietic stem cell transplantation", 
      "total serum bilirubin levels", 
      "plasminogen activator", 
      "severe hemorrhagic complications", 
      "days post transplant", 
      "stem cell transplantation", 
      "serum bilirubin levels", 
      "beginning of treatment", 
      "manifestations of disease", 
      "rtPA treatment", 
      "maximum bilirubin", 
      "post transplant", 
      "starting dose", 
      "hemorrhagic complications", 
      "creatinine levels", 
      "cell transplantation", 
      "median number", 
      "day 100", 
      "patients", 
      "probability of survival", 
      "therapy", 
      "terms of days", 
      "past history", 
      "responders", 
      "disease", 
      "dose", 
      "optimum duration", 
      "treatment", 
      "dysfunction", 
      "optimum dose", 
      "heparin", 
      "days", 
      "complications", 
      "transplantation", 
      "transplant", 
      "levels", 
      "activator", 
      "bilirubin", 
      "doses", 
      "response", 
      "median", 
      "survival", 
      "manifestations", 
      "outcomes", 
      "downward trend", 
      "onset", 
      "duration", 
      "group", 
      "differences", 
      "history", 
      "role", 
      "number", 
      "importance", 
      "trends", 
      "beginning", 
      "probability", 
      "terms"
    ], 
    "name": "Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)", 
    "pagination": "803-807", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007632827"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bmt.1701654"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10231143"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bmt.1701654", 
      "https://app.dimensions.ai/details/publication/pub.1007632827"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_343.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bmt.1701654"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701654'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701654'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701654'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701654'


 

This table displays all metadata directly associated to this object as RDF triples.

226 TRIPLES      20 PREDICATES      99 URIs      91 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bmt.1701654 schema:about N23c9c7e87e9d4c3c90b0e68da643b79d
2 N24700dc8e0d2434da50af524a79bb308
3 N3e23d01d18814a869dfd20ffbefec106
4 N72f0797ac14b46bd9a77a22360d32051
5 N9d1d16a3b2124e9884ad45d0d905da89
6 N9fa8662042094e90b9a0286327ffeb06
7 Nd0ded0483043454aae89a20e92b18168
8 Nd7bfda53fc0b4c66961ed27bc42e4e78
9 anzsrc-for:11
10 anzsrc-for:1103
11 schema:author Nd7d3cd77c31a4a3baa1b4d742e0a1c1b
12 schema:datePublished 1999-04-01
13 schema:datePublishedReg 1999-04-01
14 schema:description Seventeen patients who developed hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation were treated with recombinant tissue plasminogen activator (rtPA) with or without heparin. rtPA was started a median of 13 days post transplant (range 4–35). All patients received rtPA at a dose of 10 mg/day as a starting dose, and 12 patients also received heparin (1500 U bolus; then 100 U/kg/day as a continuous i.v. infusion). The median number of days of rtPA therapy was 2.5 (1–12). The median total serum bilirubin level was 116 mmol/l (range 63–194) at the beginning of treatment. Six patients showed a response to rtPA treatment (29%). It was observed that by day 2 of rtPA therapy, bilirubin levels in responders showed a downwards trend as compared to those in non-responders. In all except one patient this response was observed after two doses of rtPA. Seven out of the 11 non-responders had a past history of liver dysfunction, compared with none of the responders. There were no differences between the two groups in terms of day of onset of liver dysfunction, manifestations of disease, maximum bilirubin and creatinine levels, and day of commencing treatment. No patient experienced severe hemorrhagic complications during therapy. Four responders survived for more than 100 days compared to none of the non-responders. Probability of survival was 33% at day 100. It is difficult to unequivocally establish the role of rtPA in the treatment of VOD. The importance of bilirubin levels on days 2 or 3 of therapy in predicting outcome should be established, as should the optimum dose of rtPA and optimum duration of therapy.
15 schema:genre article
16 schema:isAccessibleForFree false
17 schema:isPartOf N99de36c0b4ae419f89333b7578742429
18 Nb78a8cee6f6a45bcbe717298748777ea
19 sg:journal.1096890
20 schema:keywords activator
21 beginning
22 beginning of treatment
23 bilirubin
24 bilirubin levels
25 cell transplantation
26 complications
27 creatinine levels
28 day 100
29 day 2
30 days
31 days post transplant
32 differences
33 disease
34 dose
35 doses
36 downward trend
37 duration
38 dysfunction
39 group
40 hematopoietic stem cell transplantation
41 hemorrhagic complications
42 heparin
43 hepatic veno-occlusive disease
44 history
45 importance
46 levels
47 liver dysfunction
48 manifestations
49 manifestations of disease
50 maximum bilirubin
51 median
52 median number
53 number
54 onset
55 optimum dose
56 optimum duration
57 outcomes
58 past history
59 patients
60 plasminogen activator
61 post transplant
62 probability
63 probability of survival
64 recombinant tissue plasminogen activator
65 responders
66 response
67 role
68 rtPA therapy
69 rtPA treatment
70 serum bilirubin levels
71 severe hemorrhagic complications
72 starting dose
73 stem cell transplantation
74 survival
75 terms
76 terms of days
77 therapy
78 tissue plasminogen activator
79 total serum bilirubin levels
80 transplant
81 transplantation
82 treatment
83 treatment of VOD
84 trends
85 veno-occlusive disease
86 schema:name Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)
87 schema:pagination 803-807
88 schema:productId N4f0ef861d9a34ec585fb82070048a73a
89 N90178cf4847c4b7b91753c80ef9d0386
90 Nb780797ea7754baa9e8f19fb75ecda05
91 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007632827
92 https://doi.org/10.1038/sj.bmt.1701654
93 schema:sdDatePublished 2022-10-01T06:31
94 schema:sdLicense https://scigraph.springernature.com/explorer/license/
95 schema:sdPublisher Nddbe3b8f527c4f599598eb70c4cf997f
96 schema:url https://doi.org/10.1038/sj.bmt.1701654
97 sgo:license sg:explorer/license/
98 sgo:sdDataset articles
99 rdf:type schema:ScholarlyArticle
100 N0e901223c42c4a39a2b30a4e381d174f rdf:first sg:person.0700414221.40
101 rdf:rest N9ecde4cde75b49dda7f8ce64e8411ec2
102 N138722e9bbc04534b936b87d0cebf257 rdf:first sg:person.016453351654.93
103 rdf:rest Neb3f25b032db4c2c8e2dc46ed9f5cbab
104 N23c9c7e87e9d4c3c90b0e68da643b79d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Recombinant Proteins
106 rdf:type schema:DefinedTerm
107 N24700dc8e0d2434da50af524a79bb308 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Hepatic Veno-Occlusive Disease
109 rdf:type schema:DefinedTerm
110 N3e23d01d18814a869dfd20ffbefec106 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Hematopoietic Stem Cell Transplantation
112 rdf:type schema:DefinedTerm
113 N4209e9acac5e42ed8db081a17ef43799 rdf:first sg:person.01145473407.31
114 rdf:rest Ne3216e565aa64e369f6336fa7153fd83
115 N4f0ef861d9a34ec585fb82070048a73a schema:name pubmed_id
116 schema:value 10231143
117 rdf:type schema:PropertyValue
118 N72f0797ac14b46bd9a77a22360d32051 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 N7d62b5d058274d5ebafd0061af38fe11 schema:affiliation grid-institutes:None
122 schema:familyName Mateos
123 schema:givenName P
124 rdf:type schema:Person
125 N90178cf4847c4b7b91753c80ef9d0386 schema:name doi
126 schema:value 10.1038/sj.bmt.1701654
127 rdf:type schema:PropertyValue
128 N99de36c0b4ae419f89333b7578742429 schema:volumeNumber 23
129 rdf:type schema:PublicationVolume
130 N9d1d16a3b2124e9884ad45d0d905da89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Tissue Plasminogen Activator
132 rdf:type schema:DefinedTerm
133 N9ecde4cde75b49dda7f8ce64e8411ec2 rdf:first sg:person.0753037103.30
134 rdf:rest N138722e9bbc04534b936b87d0cebf257
135 N9fa8662042094e90b9a0286327ffeb06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Bilirubin
137 rdf:type schema:DefinedTerm
138 Nb780797ea7754baa9e8f19fb75ecda05 schema:name dimensions_id
139 schema:value pub.1007632827
140 rdf:type schema:PropertyValue
141 Nb78a8cee6f6a45bcbe717298748777ea schema:issueNumber 8
142 rdf:type schema:PublicationIssue
143 Nbb9505dd2c6c4179aa06fb3606c9d5a6 schema:affiliation grid-institutes:None
144 schema:familyName Lafuente
145 schema:givenName A
146 rdf:type schema:Person
147 Nca31815597b5427c8648b5e4d1c30b8b rdf:first Ndb43594089bd4afd85e369c7fb4a3a8c
148 rdf:rest Nd056f88525ea440e8352ce75118f9f7e
149 Nd056f88525ea440e8352ce75118f9f7e rdf:first Nbb9505dd2c6c4179aa06fb3606c9d5a6
150 rdf:rest Nf34dcff78dce496f91c78bff6f28031c
151 Nd0ded0483043454aae89a20e92b18168 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Humans
153 rdf:type schema:DefinedTerm
154 Nd7bfda53fc0b4c66961ed27bc42e4e78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Adult
156 rdf:type schema:DefinedTerm
157 Nd7d3cd77c31a4a3baa1b4d742e0a1c1b rdf:first sg:person.0776532017.05
158 rdf:rest Nca31815597b5427c8648b5e4d1c30b8b
159 Ndb43594089bd4afd85e369c7fb4a3a8c schema:affiliation grid-institutes:None
160 schema:familyName Rodriguez
161 schema:givenName M
162 rdf:type schema:Person
163 Nddbe3b8f527c4f599598eb70c4cf997f schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 Ne3216e565aa64e369f6336fa7153fd83 rdf:first sg:person.01224530271.62
166 rdf:rest N0e901223c42c4a39a2b30a4e381d174f
167 Neb3f25b032db4c2c8e2dc46ed9f5cbab rdf:first sg:person.016072203544.57
168 rdf:rest rdf:nil
169 Nf34dcff78dce496f91c78bff6f28031c rdf:first N7d62b5d058274d5ebafd0061af38fe11
170 rdf:rest N4209e9acac5e42ed8db081a17ef43799
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
175 schema:name Clinical Sciences
176 rdf:type schema:DefinedTerm
177 sg:journal.1096890 schema:issn 0268-3369
178 1476-5365
179 schema:name Bone Marrow Transplantation
180 schema:publisher Springer Nature
181 rdf:type schema:Periodical
182 sg:person.01145473407.31 schema:affiliation grid-institutes:grid.5072.0
183 schema:familyName Mehta
184 schema:givenName J
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145473407.31
186 rdf:type schema:Person
187 sg:person.01224530271.62 schema:affiliation grid-institutes:grid.5072.0
188 schema:familyName Singhal
189 schema:givenName S
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224530271.62
191 rdf:type schema:Person
192 sg:person.016072203544.57 schema:affiliation grid-institutes:grid.5072.0
193 schema:familyName Powles
194 schema:givenName RL
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016072203544.57
196 rdf:type schema:Person
197 sg:person.016453351654.93 schema:affiliation grid-institutes:grid.5072.0
198 schema:familyName Treleaven
199 schema:givenName JG
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016453351654.93
201 rdf:type schema:Person
202 sg:person.0700414221.40 schema:affiliation grid-institutes:grid.5072.0
203 schema:familyName Saso
204 schema:givenName R
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700414221.40
206 rdf:type schema:Person
207 sg:person.0753037103.30 schema:affiliation grid-institutes:grid.5072.0
208 schema:familyName Tait
209 schema:givenName D
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30
211 rdf:type schema:Person
212 sg:person.0776532017.05 schema:affiliation grid-institutes:grid.5072.0
213 schema:familyName Kulkarni
214 schema:givenName S
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776532017.05
216 rdf:type schema:Person
217 grid-institutes:None schema:alternateName Haematology Department, Hospital La Paz1, Madrid, Spain
218 schema:name Haematology Department, Hospital La Paz1, Madrid, Spain
219 rdf:type schema:Organization
220 grid-institutes:grid.5072.0 schema:alternateName Department of Haematology, Royal Marsden NHS Trust, Sutton, Surrey, UK
221 Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK
222 Department of Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK
223 schema:name Department of Haematology, Royal Marsden NHS Trust, Sutton, Surrey, UK
224 Department of Medical Oncology, Royal Marsden NHS Trust, Sutton, Surrey, UK
225 Department of Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK
226 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...